Determination of stress-induced degradation products of cetirizine dihydrochloride by a stability-indicating RP-HPLC method
DARU, Journal of Pharmaceutical Sciences, ISSN: 2008-2231, Vol: 22, Issue: 1, Page: 82
2014
- 4Citations
- 33Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- CrossRef1
- Captures33
- Readers33
- 31
Article Description
Background: A new, simple and accurate stability-indicating reverse phase high performance liquid chromatography method was developed and validated during the early stage of drug development of an oral lyophilizate dosage form of cetirizine dihydrochloride. Methods: For RP-HPLC analysis it was used an Eclipse XDB C8 column 150 mm × 4.6 mm, 5 μm (Agilent columns, Barcelona, Spain) as the stationary phase with a mobile phase consisted of a mixture of 0.2 M K2HPO4 pH 7.00 and acetonitrile (65:35, v/v) at a flow rate of 1 mL min -1. Detection was performed at 230 nm using diode array detector. The method was validated in accordance with ICH guidelines with respect to linearity, accuracy, precision, specificity, limit of detection and quantification. Results: The method results in excellent separation between the drug substance and its stress-induced degradation products. The peak purity factor is >950 for the drug substance after all types of stress, which confirms the complete separation of the drug substance peak from its stress induced degradation products. Regression analysis showed r2∈>∈0.999 for cetirizine dihydrochloride in the concentration range of 650 μg mL -1 to 350 μg mL-1 for drug substance assay and a r2∈>∈0.999 in the concentration range of 0.25 μg mL-1 to 5 μg mL-1 for degradation products. The method presents a limit of detection of 0.056 μg mL -1 and a limit of quantification of 0.25 μg mL-1. The obtained results for precision and accuracy for drug substance and degradation products are within the specifications established for the validation of the method. Conclusions: The proposed stability-indicating method developed in the early phase of drug development proved to be a simple, sensitive, accurate, precise, reproducible and therefore useful for the following stages of the cetirizine dihydrochloride oral lyophilizate dosage form development.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84927918942&origin=inward; http://dx.doi.org/10.1186/s40199-014-0082-5; http://www.ncbi.nlm.nih.gov/pubmed/25487685; http://link.springer.com/10.1186/s40199-014-0082-5; http://www.darujps.com/content/22/1/82; http://dx.doi.org/10.1186/preaccept-2325316221462835; https://dx.doi.org/10.1186/preaccept-2325316221462835; https://link.springer.com/article/10.1186/s40199-014-0082-5; https://dx.doi.org/10.1186/s40199-014-0082-5
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know